RxDoctor Payments Data

Ferdinand Rodriguez Agramonte, MD

Ophthalmology · Blue Ash, OHNPI 1477971992

Payments from drug & device makers

$6,127in general payments, 2019–2025

Across 58 payments — averaging $105.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$4K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Mallinckrodt Hospital Products Inc.$326
  • Apellis Pharmaceuticals, Inc.$250
  • AbbVie$235
  • Alcon Puerto Rico Inc$202
  • plus $374 from 7 others

What the payments were for

  • Consulting fees$2,11535%
  • Food & beverage$3,83563%
  • Education$1783%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,127 in reported general payments places this provider in the 80th percentile of 640 ophthalmology providers in Ohio.

See all ophthalmology providers in Ohio

Medicare billing

Part B allowed, 2024
$129,510
Medicare patients
102
Services billed
2,538

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VabysmoFaricimab-Svoa57$130,602
Prednisolone Acetate369$13,918
LumiganBimatoprost29$8,581
Alphagan PBrimonidine Tartrate41$7,972
Brimonidine Tartrate161$6,973
Atropine Sulfate163$6,003
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol39$5,407
Ofloxacin187$4,286
Ketorolac Tromethamine194$4,071
CombiganBrimonidine Tartrate/Timolol19$3,922
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat103$3,355
Difluprednate25$3,056
Dorzolamide Hcl66$2,021
Latanoprost110$1,546
ValacyclovirValacyclovir Hcl13$1,541

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Genentech USA, Inc.Vabysmo$3,701$130,60257 claims
AbbVieLumigan, Alphagan P, Combigan$235$20,47589 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 640 ophthalmology providers in Ohio.

Other ophthalmology in Blue Ash

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →